Teva announces fda filing acceptance for ajovy® (fremanezumab) in pediatric episodic migraine prevention

Parsippany, n.j. and tel aviv, april 07, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), announced today that the u.s. food and drug administration (fda) has accepted its supplemental biologics license application (sbla) for ajovy® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. if approved, ajovy would be the only calcitonin gene-related peptide (cgrp) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address the high unmet need for effective treatments for those living with migraine.
TEVA Ratings Summary
TEVA Quant Ranking